Pancreatic Cancer Research

ResearcherVeterans Health AdministrationActive in the last 2 years

Bassel F. El‐Rayes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2661-5746; OpenAlex author ID A5057176768, A5132553064; NIH RePORTER profile ID 8454775. Sources: ClinicalTrials.gov.

Their work

Papers
76 (first author 6, last author 30)
Trials
1 (principal investigator on 1)
Grants
5
Labs led
4
Collaborators
215
Papers, trials and grants by year

2011: 1 paper, 1 trial · 2012: 1 paper · 2013: 4 papers · 2014: 5 papers · 2015: 6 papers · 2016: 9 papers · 2017: 1 paper · 2018: 4 papers · 2019: 6 papers · 2020: 5 papers · 2021: 3 papers · 2022: 5 papers · 2023: 5 papers, 3 grants · 2024: 2 papers · 2025: 8 papers · 2026: 11 papers, 2 grants

Papers 50 of 76

  1. Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-026-12810-2↗
  2. A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling. Co-author DOI 10.1016/j.canlet.2025.218233↗
  3. XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218804↗
  4. Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions. Last author DOI 10.1038/s41392-026-02705-5↗
  5. Variable efficacy of the non-covalent KRAS G12D inhibitor (MRTX-1133) with obesity in murine pancreatic cancer. Co-author DOI 10.1038/s41698-026-01493-z↗
  6. "Horses out of the barn": pancreatic ductal adenocarcinoma frequently extends beyond the grossly visible tumour, requiring microscopic rectification for accura… Co-author DOI 10.1111/his.70099↗
  7. High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-1697↗
  8. Correction: Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-26-0614↗
  9. Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy. Last author DOI 10.1186/s12943-026-02725-3↗
  10. ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment Last author DOI 10.64898/2026.01.15.699725↗
  11. ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma Last author DOI 10.64898/2026.02.11.705411↗
  12. Emerging therapeutic advancements in pancreatic cancer: a contemporary review. Last author DOI 10.1007/s12672-025-03027-8↗
  13. Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A sing… Last author DOI 10.1016/j.canlet.2025.217809↗
  14. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  15. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Last author DOI 10.1016/j.xcrm.2024.101881↗
  16. Paricalcitol and hydroxychloroquine modulates extracellular matrix and enhance chemotherapy efficacy in pancreatic cancer. Last author DOI 10.1038/s41417-025-00967-9↗
  17. Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.11.21.689857↗
  18. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12943-025-02288-9↗
  19. PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer Co-author DOI 10.64898/2025.12.06.692635↗
  20. Deciphering cellular plasticity in pancreatic cancer for effective treatments. Co-author DOI 10.1007/s10555-023-10164-5↗
  21. RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. Co-author DOI 10.1016/j.canlet.2024.217275↗
  22. Time to treatment initiation and its impact on real-world survival in metastatic colorectal cancer and pancreatic cancer. Co-author DOI 10.1002/cam4.5133↗
  23. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions. Last author DOI 10.1016/j.cytogfr.2023.06.006↗
  24. Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). Co-author DOI 10.1016/j.ejca.2023.02.030↗
  25. Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistance: A brief overview. Last author DOI 10.1016/j.semcancer.2022.12.004↗
  26. Survival and Prognostic Factors in Patients With Pancreatic Colloid Carcinoma Compared With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002227↗
  27. Connecting the Human Microbiome and Pancreatic Cancer. Co-author DOI 10.1007/s10555-022-10022-w↗
  28. Correction to: Connecting the human microbiome and pancreatic cancer. Co-author DOI 10.1007/s10555-022-10037-3↗
  29. Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy. Last author DOI 10.1016/j.cytogfr.2022.09.001↗
  30. Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-022-34242-4↗
  31. Mismatch Repair-Deficient Metastatic Pancreatic Cancer: A Letter to the Editor. Last author DOI 10.1097/mpa.0000000000002123↗
  32. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Co-author DOI 10.1007/s10555-021-09990-2↗
  33. Survival Outcomes of Acinar Cell Pancreatic Cancer: A National Cancer Database Analysis. Last author DOI 10.1097/mpa.0000000000001788↗
  34. Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-19-0911↗
  35. In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. Last author DOI 10.1016/j.jgo.2019.10.012↗
  36. Young Adults With Pancreatic Cancer: National Trends in Treatment and Outcomes. Last author DOI 10.1097/mpa.0000000000001502↗
  37. Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001584↗
  38. Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer. First author DOI 10.1136/jitc-2020-001100↗
  39. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. Co-author DOI 10.1172/jci.insight.130362↗
  40. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Last author DOI 10.1002/cncr.31787↗
  41. Curcumin analogs: Their roles in pancreatic cancer growth and metastasis. Last author DOI 10.1002/ijc.31867↗
  42. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. Last author DOI 10.1002/ijc.32227↗
  43. Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions. First author DOI 10.1007/s12029-018-0179-z↗
  44. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  45. Induction Therapy in Localized Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001353↗
  46. Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2018.03.016↗
  47. Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-6322-4↗
  48. Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Last author DOI 10.1634/theoncologist.2017-0487↗
  49. The Potential of CAR T Cell Therapy in Pancreatic Cancer. Co-author DOI 10.3389/fimmu.2018.02166↗
  50. Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. Co-author DOI 10.1002/cncr.30944↗

Trials 1

  1. Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin Principal investigator NCT01434459↗

Grants 5

  1. DCE-MRI guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer R01CA290435↗
  2. ProAgio in Pancreatic Cancer R01CA294647↗
  3. Targeting immune stroma interactions in pancreatic cancer R01CA228406↗
  4. Modulation of the human pancreatic microenvironment by combined cytokine and immune checkpoint blockade R21CA266088↗
  5. Disposable Perfusion Phantom for Accurate DCE-MRI Measurement of Pancreatic Cancer Therapy Response UH3CA232820↗

Closest collaborators

The 25 strongest of 215 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ganji Purnachandra Nagaraju · 25 shared papers, 2012–2026 · strength 4.09
  2. Gregory B. Lesinski · 12 shared papers, 2 shared grants, 2016–2026 · strength 3.31
  3. Mehmet Akce · 17 shared papers, 2018–2026 · strength 3.16
  4. Harrison Kim · 2 shared papers, 2 shared grants, 2023–2026 · strength 2.28
  5. Sujith Sarvesh · 9 shared papers, 2023–2026 · strength 2.21
  6. Dhana Sekhar Reddy Bandi · 9 shared papers, 2023–2026 · strength 2.21
  7. Shishir Kumar Maithel · 23 shared papers, 2013–2026 · strength 1.95
  8. Zhi-Ren Liu · 2 shared papers, 1 shared grant, 2026 · strength 1.82
  9. Asfar Sohail Azmi · 10 shared papers, 2021–2026 · strength 1.78
  10. Olatunji Boladale Alese · 12 shared papers, 2016–2026 · strength 1.59
  11. Walid Labib Shaib · 15 shared papers, 2016–2023 · strength 1.51
  12. Juan Manuel Sarmiento · 13 shared papers, 2014–2026 · strength 1.42
  13. Jeremy B. Foote · 6 shared papers, 2025–2026 · strength 1.41
  14. Md. Hafiz Uddin · 8 shared papers, 2021–2026 · strength 1.37
  15. Sahar F. Bannoura · 7 shared papers, 2021–2026 · strength 1.13
  16. Ashiq Masood · 1 shared grant, 2026 · strength 1.00
  17. David A. Kooby · 15 shared papers, 2013–2026 · strength 1.00
  18. Husain Yar Khan · 6 shared papers, 2022–2026 · strength 0.99
  19. Amro Aboukameel · 6 shared papers, 2022–2026 · strength 0.99
  20. Midhun Malla · 3 shared papers, 2025–2026 · strength 0.83
  21. Philip A. Philip · 6 shared papers, 2011–2025 · strength 0.79
  22. Batoul Farran · 3 shared papers, 2023–2026 · strength 0.79
  23. Michael B. Ware · 5 shared papers, 2020–2026 · strength 0.76
  24. Ashiq Masood · 3 shared papers, 2025–2026 · strength 0.73
  25. Boris Pasche · 4 shared papers, 2024–2026 · strength 0.72

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.